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Abstract 
Magnesium deficiency can cause a variety of symptoms, 
including potentially life-threatening complications 
such as seizures, cardiac arrhythmias and secondary 
electrolyte disturbances. Hypomagnesemia can be a 
serious adverse effect to proton pump inhibitor (PPI) 
therapy, which is worrying due to the widespread use 
of PPIs. Current evidence suggest that the mechanism 
of PPI induced hypomagnesemia is impaired intestinal 
magnesium absorption. In this report, we present the case 
of a long-term PPI user with persistent hypomagnesemia 
with severe symptoms at presentation. He was unable 
to stop PPI treatment because of severe reflux 
symptoms, and was dependent on weekly intravenous 
magnesium infusions, until his magnesium levels finally 
normalized without the need for supplementation after 
a successful laparoscopic fundoplication.
Key words: Hypomagnesemia; Proton pump inhibitor; 
Gastroesophageal reflux disease; Drug adverse effect; 
Laparoscopic fundoplication
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: This case illustrates a long-term proton pump 
inhibitor (PPI) user with persistent hypomagnesaemia 
causing severe symptoms at presentation. For years, 
he was dependent on oral and later intravenous 
magnesium supplementation, until his hypomagnesemia 
rapidly improved upon PPI discontinuation. He was, 
however, not able to cope with the resulting reflux 
symptoms, and was not able to completely stop PPI 
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treatment until he underwent a successful laparoscopic 
fundoplication.
Semb S, Helgstrand F, Hjørne F, Bytzer P. Persistent severe 
hypomagnesemia caused by proton pump inhibitor resolved 
after laparoscopic fundoplication. World J Gastroenterol 2017; 
23(37): 6907-6910  Available from: URL: http://www.wjgnet.
com/1007-9327/full/v23/i37/6907.htm DOI: http://dx.doi.
org/10.3748/wjg.v23.i37.6907
INTRODUCTION
Magnesium plays an essential role in several physio­
logical and biochemical bodily processes. Consequently, 
magnesium deficiency can cause a variety of symptoms, 
ranging from nonspecific complaints of weakness, 
fatigue and nausea to potentially life threatening 
complications such as seizures, cardiac arrhythmias and 
secondary electrolyte disturbances. Hypomagnesemia 
can develop due to gastrointestinal and/or renal disease, 
as well as an adverse effect to several medications. 
Several reports of severe hypomagnesemia associated 
with long term proton pump inhibitor (PPI) therapy[1,2] 
is causing concern due to the widespread use of PPIs[3]. 
Current evidence suggest that PPI impair the intestinal 
magnesium absorption through a molecular effect on 
magnesium transporters in genetically predisposed 
individuals[4]. 
We present the first case of a long-term PPI user 
with severe and symptomatic persistent hypomag-
nesemia treated with surgery. Due to severe reflux, 
the patient was PPI dependent, and needed weekly 
intravenous magnesium infusions. After a successful 
laparoscopic fundoplication, the PPI treatment could 
be discontinued, and the magnesium levels normalized 
without the need for supplementation. 
CASE REPORT
A 67-year-old male with a history of gastroesophageal 
reflux disease (GERD) and hypertension, first presented 
with severe hypomagnesemia during a hospital 
admission in 2012. At that time, he was taking 10 
mg amlodipine and 20-40 mg omeprazole daily. Prior 
to admission, he had suffered from severe dizziness, 
double sight and vomiting for several weeks, and 
was initially dehydrated with electrolyte derangement 
(hypokalemia). A few days after admission he 
developed general seizures, and additional laboratory 
tests revealed severe hypomagnesemia [0.23 mmol/L 
(0.71-0.94 mmol/L)], considered a result of excessive 
vomiting prior to admission. His serum electrolyte 
levels normalized upon intravenous treatment. An 
extensive work-up resulted in a possible diagnosis of 
viral encephalitis, and after discharge, he underwent 
a prolonged rehabilitation course. A year later, he 
was re-admitted because of dizziness, balance 
problems and paresthesia. Laboratory results again 
showed severe hypomagnesemia (0.08 mmol/L). He 
received intravenous magnesium infusions and his 
symptoms disappeared. During ambulatory follow-up, 
he was found to have persistent hypomagnesemia, 
and oral magnesium was prescribed. He underwent 
endocrinological and gastrointestinal investigations 
including colonoscopy, which did not reveal any 
other cause of his hypomagnesemia. His urinary 
magnesium level was low (< 0.080 mmol/L). Despite 
oral magnesium supplementation, magnesium 
levels continued to stay low, and in 2015, he was 
started on weekly magnesium infusions to maintain 
normal magnesium levels. The only medication he 
was on during these years was omeprazol 20-40 
mg daily. He had been advised several times during 
the years to stop PPI treatment, but was unable to 
cope with the resulting reflux symptoms. In April 
2016, he did, however, agree to stop taking PPI and 
consequently maintained normal magnesium levels 
without infusions. 24-h pH testing confirmed reflux 
disease, and he was offered anti-reflux surgery 
(laparoscopic fundoplication). While awaiting the 
operation, he started taking daily PPI again, which 
resulted in a prompt drop in his serum magnesium 
levels demanding a resumption of weekly magnesium 
infusions. The patient underwent a laparoscopic fun-
doplication and was discharged after an uncomplicated 
peri-and postoperative course. After the operation, 
the reflux symptoms as well as the need for PPI 
disappeared, and his magnesium level maintained 
normal without supplementation at the follow-up 
visit. The course of the patient’s magnesium levels is 
illustrated in Figure 1. 
DISCUSSION
This rare case illustrates a long-term PPI user with 
persistent hypomagnesemia causing severe symptoms 
at presentation. For years, he was dependent on 
oral and later weekly intravenous magnesium 
supplementation, until his hypomagnesemia rapidly 
improved upon PPI discontinuation. Re-challenge of 
PPI treatment resulted in a prompt drop in serum 
magnesium within days, and his magnesium levels 
again normalized rapidly following PPI withdrawal after 
laparoscopic fundoplication. 
PPI-induced hypomagnesemia (PPIH) was first 
described by Epstein et al [5] in 2006, and subsequently 
several other case reports have demonstrated the 
association. In 2011, the United States Food and 
Drug Administration issued a safety announcement 
regarding the association between long term PPI 
use and hypomagnesemia, and PPIH is now well-
established as a rare, but potentially serious, adverse 
effect of long term PPI treatment. However, PPIH is still 
not widely acknowledged, and the frequency and risk 
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factors of PPIH are not well recognized. 
PPIH has been observed with all different 
formulations of PPIs and is thus considered a class 
drug effect. Similar to our case, previous reports have 
documented only partial effect of oral magnesium 
supplements in correcting the hypomagnesemia during 
ongoing PPI-therapy[2], and only short term relief 
with intravenous magnesium infusions. In contrast, 
hypomagnesemia is typically improved promptly 
after the PPI is discontinued, and PPI re-challenge 
results in rapid recurrence of hypomagnesemia[1,2]. 
The same phenomenon has not been observed with 
histamine 2 receptor antagonists (H2RAs), although 
a recent population­based study suggested a similar 
but weaker association with the use of these drugs[6]. 
Previous reports have suggested that PPIH occurs after 
long term PPI use[1]; however, duration of exposure to 
PPI therapy is often difficult to quantify retrospectively 
and the duration of PPI use necessary to cause PPIH 
remains uncertain. 
Magnesium homeostasis is mainly determined by 
absorption in the small intestine, and renal excretion. 
Intestinal magnesium absorption is complex, and occurs 
via both passive and active transport mechanisms. 
Firstly, magnesium is passively absorbed through a 
paracellular pathway between the enterocytes of the 
intestine across a concentration gradient. Secondly, 
a transcellular active transport mechanism occur by 
means of a combined action of magnesium channels 
in the apical membrane of enterocytes on the luminal 
surface, particularly transient receptor potential 
melastin (TRPM) 6 and 7. It has been proposed that 
increased luminal pH in the intestine caused by PPIs 
may alter the affinity of the TRPM6/7 channel for 
magnesium, resulting in reduced active transport of 
magnesium, and that individual genetic variations in 
the TRPM could explain why PPIH does not develop 
in all PPI users[4]. Several other drugs can cause 
hypomagnesemia, where the underlying mechanism 
is tubular magnesium wasting[1]. In contrast, previous 
case reports of PPIH have documented consistently 
low urinary excretion coherent with efficient tubular 
magnesium retention[1,2], which is thought to support 
the theory of impaired gastrointestinal absorption as 
the mechanism leading to PPIH.
Some patients might be more susceptible to 
PPIH due to other coexisting risk factors such as 
concomitant medication (diuretics) or other medical 
conditions associated with hypomagnesemia such as 
diabetes mellitus, inflammatory bowel disease, short-
bowel disease, chronic pancreatitis, diarrhea and/or 
alcoholism. It remains controversial whether serum 
magnesium should be monitored in all long-term PPI 
users, or perhaps in specific subsets of patients with 
additional risk factors. Nonetheless, PPIH should be 
remembered as a differential diagnosis in patients with 
PPI use and unexplained hypomagnesemia. Patients 
with PPIH and persistent troublesome reflux symptoms 
after PPI discontinuation could be considered for anti-
reflux surgery. It should be remembered, however, 
that a majority of patients treated with anti-reflux 
surgery have resumed PPI therapy 10-15 years after 
the operation[7], and it is mandatory to control for 
hypomagnesemia if patients with previous PPIH resume 
PPI treatment.
COMMENTS
Case characteristics
A 67-year old male with gastroesophageal reflux disease and persistent severe 
hypomagnesemia demanding weekly intravenous magnesium infusions. 
Clinical diagnosis
Extensive work-up did not reveal any other cause of hypomagnesaemia. 
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Figure 1  Course of the patient’s magnesium levels. The figure illustrates how the patient´s S-Mg level stays persistently below the normal range while he is on PPI 
therapy despite receiving magnesium infusions. S-Mg normalizes promptly after cessation of PPI therapy. PPI: Proton pump inhibitor.
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individuals.
Experiences and lessons
PPIH should be remembered as a differential diagnosis in patients with PPI 
use and unexplained hypomagnesemia. Patients with PPIH and persistent 
troublesome reflux symptoms after PPI discontinuation could be considered for 
anti-reflux surgery
Peer-review
The manuscr ipt  descr ibes surgical  opt ion in the management of 
hypomagnesemia induced by PPIs. The condition has been described earlier 
but fundoplication as an option has not been discussed in earlier reports. The 
manuscript is well written and may be accepted with few clarifications.
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Serum magnesium levels rapidly normalized upon pump inhibitor (PPI) 
discontinuation, and re-challenge of PPI treatment resulted in a prompt drop in 
serum magnesium within days. Magnesium levels again normalized following 
PPI withdrawal after laparoscopic fundoplication. 
Differential diagnosis
Gastrointestinal or renal disease causing either impaired absorption or 
increased excretion of magnesium. 
Laboratory diagnosis
Initially the patient had severe hypomagnesemia (0.23 mmol/L) with associated 
hypokalemia, which both resolved with intravenous magnesium infusions. 
However, the patient had continuously low S-Mg levels during the disease 
course despite both oral and intravenous magnesium supplementation, where 
other laboratory tests were normal. 
Imaging diagnosis
Neither colonoscopy nor CT scans revealed any other explanation for the 
patient´s persistent hypomagnesaemia. 
Pathological diagnosis
Biopsies taken from terminal ileum and colon during colonoscopy were normal.
Treatment
The patient underwent a successful laparoscopic fundoplication, and his serum 
magnesium levels again normalized following PPI withdrawal after the surgery.
Related reports
PPI-induced hypomagnesemia (PPIH) was first described in 2006, and 
subsequently several other case reports have demonstrated the association. 
In 2011, the US Food and Drug Administration issued a safety announcement 
regarding the association between long term PPI use and hypomagnesemia, 
and PPIH is now well-established as a rare, but potentially serious, adverse 
effect of long term PPI treatment.
Term explanation
PPIH is a rare, but potentially serious adverse effect where persistent severe 
hypomagnesemia is associated with of long-term PPI treatment. PPIH is 
probably caused by impaired intestinal magnesium absorption through a 
molecular effect on magnesium transporters in genetically predisposed 
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